TAAR1 and lung carcinoma: Following the early clinical studies on Tα1 in lung cancer patients (78, 79), showing that Tα1 treatment was associated with significant improvements in immune parameters, and prolonged relapse-free and overall survival, especially for patients with non-bulky tumors, subsequent studies have focused on the combination of Tα1 with chemotherapy in mouse models and human patients.